{"disease":{"id":"prostatic-neoplasms-castration-resistant","name":"prostatic neoplasms castration resistant"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05520138","title":"Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)","phase":"","overall_status":"COMPLETED","enrollment_count":5506,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05968599","title":"A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2731,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07225946","title":"A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT03016312","title":"A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":759,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04962919","title":"Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":584,"lead_sponsor_name":"Latin American Cooperative Oncology Group","has_results":false},{"nct_id":"NCT02803437","title":"Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases","phase":"","overall_status":"COMPLETED","enrollment_count":334,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04104776","title":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06353386","title":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT02899104","title":"Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04381832","title":"Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"Arcus Biosciences, Inc.","has_results":false},{"nct_id":"NCT05393791","title":"Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT03563014","title":"A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223","phase":"","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07376057","title":"Development and Prospective Validation of a Pathology-Based Artificial Intelligence Model for Predicting the Time to Castration Resistance of Prostate Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT03431350","title":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":136,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT02204072","title":"BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06788509","title":"A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":120,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04597411","title":"Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":99,"lead_sponsor_name":"Endocyte","has_results":false},{"nct_id":"NCT02450812","title":"Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04717154","title":"Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT03927391","title":"Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT02123758","title":"A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"Aragon Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04249947","title":"P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"Poseida Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03017417","title":"A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Sheffield Teaching Hospitals NHS Foundation Trust","has_results":false},{"nct_id":"NCT05902247","title":"Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT05743621","title":"Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT03389451","title":"68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Michael Graham PhD, MD","has_results":true},{"nct_id":"NCT05156450","title":"TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT02349139","title":"Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Asana BioSciences","has_results":false},{"nct_id":"NCT02625857","title":"Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02592317","title":"A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":23,"lead_sponsor_name":"Aragon Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03388346","title":"68Ga PSMA in Preprostatectomy Patients","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Michael Graham PhD, MD","has_results":true},{"nct_id":"NCT06706921","title":"18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"VA Greater Los Angeles Healthcare System","has_results":false},{"nct_id":"NCT06136598","title":"A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT05169684","title":"A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT03526562","title":"Exercise Prescription Dose for Castration Resistance Prostate Cancer Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT06104449","title":"A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT02162836","title":"A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Janssen Pharmaceutical K.K.","has_results":false},{"nct_id":"NCT03822845","title":"Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Michael Graham PhD, MD","has_results":true},{"nct_id":"NCT05633160","title":"64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Clarity Pharmaceuticals Ltd","has_results":false},{"nct_id":"NCT03325127","title":"Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04854369","title":"68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly)","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Tulane University","has_results":false}],"total":41},"guidelines":[],"source":"Drug Landscape verified database"}